Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Pevifoscorvir sodium (ALG-000184) in Chronic hepatitis B. The expected timing is based on the latest available company guidance and may change.
B-SUPREME study. 7/18/24- Ph1b results at KOL event. 3/28/25- Ph1 Preliminary data at APASL'25. 8/13/25- First patient dosed. 11/6/25- Interim data in H1 & H2 2026. 11/10/25- Presentation at AASLD'25. 01/21/26:- B-SUPREME enrolling 144 subjects. Interim analyses H1 and H2 2026; topline Phase 2 data expected 2027. 02/23/26:- Ph1 monotherapy data in chronic HBV presented at CROI 2026. 03/05/26:- B-SUPREME HBeAg- cohort fully enrolled; interim analyses in H1 and H2 2026; topline cohort data expected 2027. 04/14/26:- FDA Fast Track granted. DSMB recommends continue, enlarge HBeAg- cohort. Second interim expected H2 2026; topline 2027. 05/07/26:- First B-SUPREME interim analysis positive; DSMB expanded HBeAg- cohort; second interim H2 2026; Phase 1 EASL 2026 data. 05/13/26:- EASL 2026 posters May 27-28 cover 96-week monotherapy follow-up and population PK results. 05/27/26:- Ph1 follow-up data at EASL 2026. Next Phase 2 interim remains H2 2026. 07/13/26:- B-SUPREME fully enrolled; second interim canceled. Topline Ph2 safety and efficacy data expected Late Q3 2027. 08/06/26:- B-SUPREME enrollment complete; China Breakthrough granted; topline Ph2 data expected Late Q3 2027.
Verification
Confirm timing and program details against the company announcement or filing.